The medical community is abuzz with anticipation surrounding retatrutide, a innovative dual GIP and GLP-1 agonist that’s demonstrating significant promise in clinical trials for treating obesity. Unlike some available weight loss treatments, retatrutide appears to provide a more substantial reduction in body size and improve metabolic health, par